Bridgebio Oncology Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on advancing a next-generation pipeline of novel small molecule therapeutics targeting RAS and PI3Ka malignancies. The company was founded on August 1, 2016 and is headquartered in South San Francisco, CA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A
Frequently Asked Questions
What is Market Cap of BridgeBio Oncology Therapeutics Inc.?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. BridgeBio Oncology Therapeutics Inc. market cap is $942.29M.
What is the 52-week high for BridgeBio Oncology Therapeutics Inc.?
52 week high is the highest price of a stock in the past 52 weeks, or one year. BridgeBio Oncology Therapeutics Inc. 52 week high is $12.50 as of September 24, 2025.
What is the 52-week low for BridgeBio Oncology Therapeutics Inc.?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. BridgeBio Oncology Therapeutics Inc. 52 week low is $8.70 as of September 24, 2025.
What is BridgeBio Oncology Therapeutics Inc. stock price today?
BridgeBio Oncology Therapeutics Inc. stock price today is $11.38.
What was BridgeBio Oncology Therapeutics Inc. stock price yesterday?
BridgeBio Oncology Therapeutics Inc. stock price yesterday was $11.25.
What is the PE ratio of BridgeBio Oncology Therapeutics Inc.?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. BridgeBio Oncology Therapeutics Inc.’s P/E ratio is 56.03.
What is the Price-to-Book ratio of BridgeBio Oncology Therapeutics Inc.?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. BridgeBio Oncology Therapeutics Inc. P/B ratio is 1.3969.
What is the 50-day moving average of BridgeBio Oncology Therapeutics Inc.?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. BridgeBio Oncology Therapeutics Inc. 50-day moving average is $10.16.